KR20250073570A - 간세포성 암종의 치료를 위한 조합 요법 - Google Patents

간세포성 암종의 치료를 위한 조합 요법 Download PDF

Info

Publication number
KR20250073570A
KR20250073570A KR1020257016389A KR20257016389A KR20250073570A KR 20250073570 A KR20250073570 A KR 20250073570A KR 1020257016389 A KR1020257016389 A KR 1020257016389A KR 20257016389 A KR20257016389 A KR 20257016389A KR 20250073570 A KR20250073570 A KR 20250073570A
Authority
KR
South Korea
Prior art keywords
acid
lenvatinib
compound
combination
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257016389A
Other languages
English (en)
Korean (ko)
Inventor
아난드 셀바라즈
피터 스미스
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20250073570A publication Critical patent/KR20250073570A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020257016389A 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법 Pending KR20250073570A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862615848P 2018-01-10 2018-01-10
US62/615,848 2018-01-10
PCT/US2019/012886 WO2019139977A1 (en) 2018-01-10 2019-01-09 Combination therapies for the treatment of hepatocellular carcinoma
KR1020207022999A KR102811519B1 (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207022999A Division KR102811519B1 (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Publications (1)

Publication Number Publication Date
KR20250073570A true KR20250073570A (ko) 2025-05-27

Family

ID=65411938

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257016389A Pending KR20250073570A (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법
KR1020207022999A Active KR102811519B1 (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207022999A Active KR102811519B1 (ko) 2018-01-10 2019-01-09 간세포성 암종의 치료를 위한 조합 요법

Country Status (13)

Country Link
US (1) US11833119B2 (cg-RX-API-DMAC10.html)
EP (2) EP3737377B1 (cg-RX-API-DMAC10.html)
JP (2) JP7352569B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250073570A (cg-RX-API-DMAC10.html)
CN (1) CN111787922A (cg-RX-API-DMAC10.html)
AU (1) AU2019206480A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020014112A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088292A1 (cg-RX-API-DMAC10.html)
IL (1) IL275981A (cg-RX-API-DMAC10.html)
MA (1) MA51570A (cg-RX-API-DMAC10.html)
MX (1) MX2020007375A (cg-RX-API-DMAC10.html)
SG (1) SG11202006617RA (cg-RX-API-DMAC10.html)
WO (1) WO2019139977A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Fgfr4阻害剤の経口製剤によるがんの治療方法
KR20250003965A (ko) 2022-05-30 2025-01-07 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 암 치료용 약학적 조합 및 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
CA2704000C (en) * 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
CN105338977B (zh) * 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
US10736900B2 (en) * 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US20160089365A1 (en) * 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound
CN107660200B (zh) 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN107304188A (zh) * 2016-04-20 2017-10-31 成都融科博海科技有限公司 一种氘代激酶选择性抑制剂及其应用
JP7372740B2 (ja) * 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ

Also Published As

Publication number Publication date
IL275981A (en) 2020-08-31
RU2020126673A3 (cg-RX-API-DMAC10.html) 2022-04-19
CN111787922A (zh) 2020-10-16
RU2020126673A (ru) 2022-02-10
KR102811519B1 (ko) 2025-05-22
KR20200121302A (ko) 2020-10-23
JP7665700B2 (ja) 2025-04-21
JP2023175825A (ja) 2023-12-12
EP4667005A2 (en) 2025-12-24
EP3737377B1 (en) 2025-10-08
JP7352569B2 (ja) 2023-09-28
MA51570A (fr) 2020-11-18
US11833119B2 (en) 2023-12-05
JP2021512140A (ja) 2021-05-13
EP3737377A1 (en) 2020-11-18
SG11202006617RA (en) 2020-08-28
CA3088292A1 (en) 2019-07-18
AU2019206480A1 (en) 2020-08-27
MX2020007375A (es) 2020-11-09
EP4667005A3 (en) 2026-02-18
WO2019139977A1 (en) 2019-07-18
US20200360371A1 (en) 2020-11-19
BR112020014112A2 (pt) 2020-12-01

Similar Documents

Publication Publication Date Title
EP3503923B1 (en) Combination therapies for the treatment of hepatocellular carcinoma
JP5686603B2 (ja) 使用
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
US20110251239A1 (en) Combination therapy for the treatment of dementia
JP2022160654A (ja) 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ
KR20220029717A (ko) 항암 화합물 e7766의 치료 순응도 향상을 위한 시스템
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000